Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):211-219. doi: 10.6004/jnccn.2018.7095.

2.

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.

Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X.

Blood Adv. 2018 Oct 23;2(20):2681-2690. doi: 10.1182/bloodadvances.2018021436.

3.

Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.

Dombi P, Illés Á, Demeter J, Homor L, Simon Z, Karadi E, Udvardy M, Egyed M.

Eur J Haematol. 2017 Feb;98(2):106-111. doi: 10.1111/ejh.12806. Epub 2016 Sep 19.

PMID:
27557754
4.

Hydroxyurea in old patients with essential thrombocythemia.

Randi ML, Ruzzon E, Piccoli A, Tezza F, Scapin M, Scandellari R, Fabris F.

Aging Clin Exp Res. 2008 Aug;20(4):376-80.

PMID:
18852553
5.
6.
7.
8.

Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia.

Piccin A, Steurer M, Feistritzer C, Murphy C, Eakins E, Van Schilfgaarde M, Corvetta D, Di Pierro AM, Pusceddu I, Marcheselli L, Gambato R, Langes M, Veneri D, Perbellini O, Pacquola E, Gottardi M, Gherlinzoni F, Mega A, Tauber M, Mazzoleni G, Piva E, Plebani M, Krampera M, Gastl G.

Transl Res. 2017 Jun;184:21-34. doi: 10.1016/j.trsl.2017.02.001. Epub 2017 Feb 14.

PMID:
28259616
9.

Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.

Piccin A, Steurer M, Mitterer M, Blöchl EM, Marcheselli L, Pusceddu I, Marabese A, Bertozzi I, Corvetta D, Randi ML, Elli E, Pogliani EM, Veneri D, Perbellini O, Krampera M, Pacquola E, Gottardi M, Tiribelli M, Guella A, Innella B, Vivaldi P, De Biasi E, Sancetta R, Rocconi R, Bassan R, Gherlinzoni F, Pizzolo G, Gastl G, Cortelazzo S.

Intern Emerg Med. 2015 Jun;10(4):451-60. doi: 10.1007/s11739-015-1186-8. Epub 2015 Jan 14.

PMID:
25585678
10.

Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.

Sterkers Y, Preudhomme C, Laï JL, Demory JL, Caulier MT, Wattel E, Bordessoule D, Bauters F, Fenaux P.

Blood. 1998 Jan 15;91(2):616-22.

11.

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.

Huang BT, Zeng QC, Zhao WH, Li BS, Chen RL.

Leuk Res. 2014 Oct;38(10):1177-83. doi: 10.1016/j.leukres.2014.06.019. Epub 2014 Jul 15.

PMID:
25069759
12.

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.

Caramazza D, Caracciolo C, Barone R, Malato A, Saccullo G, Cigna V, Berretta S, Schinocca L, Quintini G, Abbadessa V, Di Raimondo F, Siragusa S.

Ann Hematol. 2009 Oct;88(10):967-71. doi: 10.1007/s00277-009-0706-x. Epub 2009 Feb 13.

PMID:
19214510
13.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study.

N Engl J Med. 2005 Jul 7;353(1):33-45.

14.
15.

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T.

Blood. 2007 Mar 15;109(6):2310-3. Epub 2006 Nov 16.

16.

Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.

Samuelson B, Chai-Adisaksopha C, Garcia D.

J Thromb Thrombolysis. 2015 Nov;40(4):474-9. doi: 10.1007/s11239-015-1218-2. Review.

PMID:
25894476
17.

Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.

Latagliata R, Rago A, Spadea A, Santoro C, Carmosino I, Breccia M, Napoleone L, Fama A, Biondo F, Volpicelli P, Vozella F, Stefanizzi C, Petti MC, Alimena G, Mazzucconi MG.

Int J Hematol. 2009 Nov;90(4):486-491. doi: 10.1007/s12185-009-0401-7. Epub 2009 Aug 22.

PMID:
19701677
18.

Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.

Randi ML, Fabris F, Girolami A.

Leuk Lymphoma. 2000 Apr;37(3-4):379-85.

PMID:
10752989
19.

Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.

Radaelli F, Onida F, Rossi FG, Zilioli VR, Colombi M, Usardi P, Calori R, Zanella A.

Hematology. 2008 Aug;13(4):195-202. doi: 10.1179/102453308X316022.

PMID:
18796244
20.

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ES, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, Müllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A.

J Clin Oncol. 2011 Aug 10;29(23):3179-84. doi: 10.1200/JCO.2010.34.5298. Epub 2011 Jul 11.

PMID:
21747083

Supplemental Content

Support Center